



### Project Summary Information

Date of Document Preparation/Updating: February 10, 2022	
<b>Project Name</b>	Responsive COVID-19 Vaccines for Recovery Project
<b>Project Number</b>	P000564
<b>AIIB member</b>	Republic of India
<b>Sector/Subsector</b>	Public Health / N/A
<b>Status of Financing</b>	Approved
<b>Project Description</b>	The project will support procurement of safe and effective vaccines against COVID-19. The proposed Loan will be co-financed with the Asian Development Bank (ADB) under its rapid response component (RRC) of ADB's Asia Pacific Vaccine Access Facility (APVAX). <sup>1</sup> The loan proceeds of ADB and AIIB will finance expenditures in relation to the procurement of COVID-19 vaccines that meet the APVAX eligibility criteria <sup>2</sup> . The government will cover financial charges during implementation, including interest, commitment charges and front-end fee, in addition to in-kind contributions in the form of counterpart staff, logistics, cold chain infrastructure, and other facilities. In parallel to this Project, ADB has mobilized around USD 4 million for technical assistance <sup>3</sup> to provide catalytic operational support through program management unit, monitoring of vaccination sites, strengthening biomedical waste management capacity etc.
<b>Objective</b>	To vaccinate eligible populations against COVID-19 in states falling within the scope of the Project (project states) <sup>4</sup> .
<b>Expected Results</b>	a) Vaccination of about 317 million people in target population (at least 47.5% women) against COVID-19. b) About 667 million doses of COVID-19 vaccines procured and delivered to the project states.
<b>Environmental and Social Category</b>	Category C

<sup>1</sup> ADB's Support to Enhance COVID-19 Vaccine Access, APVAX policy paper (December 2020): <https://www.adb.org/sites/default/files/institutional-document/662801/adb-support-covid-19-vaccine-access.pdf>

<sup>2</sup> The project will be guided by the Indicative Master List of Eligible Items and Agreed List of Acceptable Expenditure Items as specified in the annex of the APVAX policy paper. See footnote 3.

<sup>3</sup> ADB 2021: Technical assistance to India: [Supporting COVID-19 Response and Vaccination Program](#)

<sup>4</sup> The project states include Uttar Pradesh, Maharashtra, Bihar, West Bengal, Tamil Nadu, Andhra Pradesh, Madhya Pradesh, Rajasthan, Karnataka, Gujarat, Odisha, Kerala, Jharkhand, Assam, Punjab, Telangana, Haryana, Chhattisgarh, and Delhi (in the order of size of eligible population).

<b>Environmental and Social Information</b>	The loan will be co-financed with ADB as the lead co-financier. The project's environmental and social (ES) risks and impacts have been assessed in accordance with ADB's Safeguard Policy Statement (SPS). To ensure a harmonized approach to addressing the ES risks and impacts of the project, and as permitted under AIIB's Environmental and Social Policy (ESP), ADB's SPS will apply to the project in lieu of AIIB's ESP. AIIB has reviewed ADB's SPS and is satisfied that: (a) it is consistent with AIIB's Articles of Agreement and materially consistent with the provisions of AIIB's ESP, including the Environmental and Social Exclusion List and the relevant Environmental and Social Standards; and (b) the monitoring procedures that are in place are appropriate for the project. Under its SPS, ADB has categorized the project as Category C for Environment, Involuntary Resettlement, and Indigenous Peoples on the basis that no adverse ES impacts are expected. The project is proposed by ADB to be categorized as effective gender mainstreaming.			
<b>Cost and Financing Plan</b>	Indicative Cost and Financing Plan			
	<b>Modality and Sources</b>	<b>Amount (\$ million)</b>	<b>Share of Total (%)</b>	
	<b>Asian Development Bank</b>	1,500.00	72.89	
	<b>Asian Infrastructure Investment Bank</b> Sovereign-Backed Financing	500.00	24.30	
	<b>Government</b>	57.77	2.81	
	<b>Total</b>	<b>2,057.77</b>	<b>100.00</b>	
<b>Borrower</b>	Republic of India			
<b>Implementing Entity</b>	Project Management Unit(s) under the Ministry of Health and Family Welfare of India			
<b>Estimated date of loan closing</b>	June 30, 2025			
<b>Contact Points:</b>	<b>AIIB</b>	<b>ADB</b>	<b>Borrower</b>	<b>Implementation Organization</b>
<b>Name</b>	Ankur Agrawal	Sonalini Khetrpal	Dr. Prasanna V. Salian	Dr. M. K. Aggarwal
<b>Title</b>	Investment Operations Specialist - Urban	Social Sector Specialist	Deputy Secretary (MI) Department of Economic Affairs Ministry of Finance	Deputy Commissioner (UIP) Ministry of Health and Family Welfare
<b>Email Address</b>	ankur.agrawal@aiib.org	skhetrapal@adb.org	pv.salian@nic.in	mk.aggarwal13@nic.in

<b>Date of Concept Decision</b>	October 2021
<b>Date of Appraisal Decision/Estimated Date of Appraisal Decision</b>	October 2021
<b>Date of Financing Approval</b>	January 20, 2022
<b>Independent Accountability Mechanism</b>	The proposed Project will be co-financed with the Asian Development Bank (ADB). ADB's SPS will apply to this project, instead of AIIB's ESP. Pursuant to AIIB's agreement with ADB, AIIB will rely on ADB's Independent Accountability Mechanism, the Accountability Mechanism, to handle complaints relating to ES matters that may arise under the project. Consequently, in accordance with AIIB's Policy on Project affected People's Mechanism (PPM), submissions to the PPM under this project will not be eligible for consideration by the PPM. Information on ADB's Accountability Mechanism is available at <a href="https://www.adb.org/site/accountability-mechanism/main">https://www.adb.org/site/accountability-mechanism/main</a>